-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Nuocheng Jianhua (688428.SH) announced that the phase IIb clinical study of the BTK inhibitor obutinib to treat systemic lupus erythematosus (“SLE”) independently developed by the company reached the main end, and was approved by the National Drug Administration (NMPA) Drug Evaluation Center (CDE) to carry out phase III registered clinical trials. The company will begin this clinical study as soon as possible.

Zhitongcaijing·12/14/2025 08:33:02
Listen to the news
Zhitong Finance App News, Nuocheng Jianhua (688428.SH) announced that the phase IIb clinical study of the BTK inhibitor obutinib to treat systemic lupus erythematosus (“SLE”) independently developed by the company reached the main end, and was approved by the National Drug Administration (NMPA) Drug Evaluation Center (CDE) to carry out phase III registered clinical trials. The company will begin this clinical study as soon as possible.